<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868580</url>
  </required_header>
  <id_info>
    <org_study_id>CUR-101</org_study_id>
    <nct_id>NCT02868580</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).</brief_title>
  <acronym>Lighthouse</acronym>
  <official_title>Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuroscience Trials Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Macquarie University, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Westmead Hosptial</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Calvary Health Care Bethlehem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Sydney - Brain and Mind Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuroscience Trials Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2a open label, multicentre design study to investigate the safety of Triumeq
      in patients with ALS at 24 weeks post treatment. In this phase 2a study the investigators aim
      to determine whether a combination of anti-retroviral therapy, Triumeq (dolutegravir 50mg,
      abacavir 600mg, lamivudine 300mg) is tolerated and safe in patients with ALS. As secondary
      outcomes, ALSFRS-R, ALSQOL, physical examination, neurophysical parameters and respiratory
      and muscle function will be evaluated. Blood and urine samples will be stored for possible
      future analysis for viral activity. Subjects will be screened for the study after signing an
      approved Informed consent document.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a multi-centre, open-label longitudinal study to investigate the safety
      and tolerability of combination antiretroviral therapy (Triumeq) in Motor Neuron Disease
      (MND)/Amyotrophic Lateral Sclerosis (ALS) for 24 weeks in 40 HIV negative ALS patients.

      The overall study duration will be 34 weeks, with up to 14 days for screening, followed by an
      8-week lead-in phase and 24-week treatment phase. Outcomes will be measured at 4, 8, 12, 20
      and 24 weeks. Participants will be followed at 4-weekly intervals for safety and clinical
      measures.

      Subjects will be screened for the study after signing an approved Informed consent form. As
      part of the 14 day screening phase, subjects will undertake an extensive medical and
      neurological assessments.

      Following the screening phase subjects will enter the 8 week lead-in-phase. During this
      phase, they will undertake two ALSFRS-R at 4 week intervals. The ALSFRS-R will be undertaken
      with the subject by telephone.

      At the baseline visit, following the lead-in-period, blood and urine will be taken for safety
      monitoring and also bio-banked for possible future measurement of Human Endogenous
      Retroviruses (HERVs). Baseline signs and symptoms will be collected.

      All subjects will have their inclusion and exclusion criteria checked at the Baseline visit
      (Week 0) and eligible subjects will start the Triumeq.

      Subjects will return to the centre on Weeks 4, 8, 16, 24 and at 7 days after the last dose of
      investigational product (or early termination) to undertake a neurological examination as
      well as an assessment of the ALS Functional Rating Scale-Revised (ALSFRS-R), neurophysical
      index (NPI), forced vital capacity (FVC) as measured by handheld spirometer, SNIP test and
      quantitative hand muscle testing by dynamometry. All subjects will undertake an evaluation of
      hematological and biochemical parameters and collection of blood and urine samples for
      bio-banking. A voice recording will be undertaken.

      At early termination visit, subjects will undergo an ECG Test. At baseline, weeks 8, 16 and
      24 or early termination visit subjects will be asked to complete the Columbia Suicide
      Severity Rating Scale. At screening week 8 and end of treatment/early termination visit,
      subjects will also be asked to complete an ALSFRS-R.

      SAE's, AE's and changes to concomitant medications will be observed and evaluated throughout
      the study. Each study visit will have a 7 day window after the due date to account for
      scheduling conflicts/holidays/weekends.

      Subjects will be given additional study product to account for the 7- day window.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Safety and Tolerability open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment related adverse events as defined CTCAE V4.0.</measure>
    <time_frame>1 year</time_frame>
    <description>Safety will be measured by Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALS Functional Rating Scale-Revised (ALSFRS-R) scoring</measure>
    <time_frame>1 year</time_frame>
    <description>Efficacy will be measured by the change in scores of the ALS Functional Rating Scale-Revised (ALSFRS-R) conducted at screening, twice within the lead-in phase and at four weekly intervals during the study until end of treatment or early termination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values for Neurophysiological Index (NI) Related to Treatment.</measure>
    <time_frame>1 year</time_frame>
    <description>A neurophysiological index (NI) measurement will be calculated according to the parameters of Compound Muscle Action Potential amplitude/DML x Frequency % to determine the index score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal Sniff Nasal Inspiratory Pressure (SNIP) Test results</measure>
    <time_frame>one year</time_frame>
    <description>The SNIP test results will be calculated according to the Pn(sn) as a percentage of predicted value according to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal forced vital capacity (FVC) test results as measured by hand-held spirometry</measure>
    <time_frame>One year</time_frame>
    <description>The FVC test results will be measured in liters and reported according to percentage of predicted values for participants on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal quantitative hand muscle testing as measured by dynanometry.</measure>
    <time_frame>One year</time_frame>
    <description>The quantitative hand muscle strength will be assessed by 3 Measurements on Grip Strength and Pinch Grip: measurement in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal scores on the Columbia Suicide Severity Score C-SSRS).</measure>
    <time_frame>One year</time_frame>
    <description>The C-SSRS is a measure of suicidal ideation and behavior. It is a composite numerical scale divided into sections and used to assess selected parameters over time in participants on treatment. The scoring system is both binomial and rating scale and is reported according to different aspects of the assessment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with abnormal ECG results</measure>
    <time_frame>one year</time_frame>
    <description>ECGs will be performed at screening, 16 and 24 weeks and early termination for participants on treatment.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Single arm open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive open label Triumeq following a lead-in phase. Triumeq is abacavir 600mg, lamivudine 300mg, dolutegravir 50mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triumeq</intervention_name>
    <description>Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.</description>
    <arm_group_label>Single arm open label</arm_group_label>
    <other_name>dolutegravir (50mg)</other_name>
    <other_name>abacavir (600mg)</other_name>
    <other_name>lamivudine (300mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria to be eligible to participate in
        this study:

          -  Age 18-75 years at the time of the screening visit

          -  Able to provide informed consent and comply with study procedures

          -  Sporadic ALS diagnosed as probable, laboratory-supported probable or definite
             according to the World Federation of Neurology El Escorial revised criteria as
             determined by a neurologist with neuromuscular sub-specialty training

          -  Diagnosis &lt;24 months from date of enrolment

          -  (Forced) Vital capacity at least 60% of predicted value for gender, height and age at
             the screening visit

          -  Must be on a stable dose of riluzole for at least 30 days prior to the screening
             visit.

          -  Subject has established care with a neurologist at one of the four specialized ALS
             clinics involved in the study and will maintain this clinical care throughout the
             study.

          -  Subjects can participate in clinical registries, but will be excluded to this protocol
             if they are participating in a clinical trial involving additional or investigative
             treatment exposure.

        Exclusion Criteria:

        A participant will be excluded if he or she has any of the following:

          -  Dependence on mechanical ventilation at the time of screening

          -  Gastrostomy at the time of screening

          -  Absence of Upper Motor Neuron Signs

          -  Participation in any other investigational drug trial or using investigational drug
             (within 12 weeks prior to screening)

          -  Known hypersensitivity to dolutegravir, abacavir or lamivudine, or to any of the
             excipients

          -  Presence of the HLA-B*5701 allele at screening

          -  Presence of a monogenic cause of ALS (e.g. known mutation in SOD1, expansion in
             c9orf72 etc.)

          -  History of positive test or positive result at screening for HIV

          -  Subjects positive for Hepatitis B at screening (+HBsAg), or anticipated need for
             Hepatitis C virus (HCV) therapy during the study*;

          -  Women must not be able to become pregnant (post menopausal for &gt;1 year, surgically
             sterile, adequate contraception) or breastfeed for the duration of the study. Women of
             childbearing potential must have a negative pregnancy test at screening and be
             non-lactating

          -  Other interventional clinical trial

          -  Subject is taking medication contraindicated with Triumeq. Dofetilide (or pilsicainide
             [available in Japan]) is prohibited as DTG may inhibit its renal tubular secretion
             resulting in increased dofetilide concentrations and potential for toxicity.

          -  Presence of any of the following clinical conditions at the time of screening:

        Drug or alcohol abuse Unstable medical disease (such as unstable angina or chronic
        obstructive pulmonary disease), or active infectious disease (such as Hepatitis B or C or
        tuberculosis), or current malignancy Unstable psychiatric illness defined as psychosis or
        untreated major depression within 90 days of the screening visit. This exclusion criteria
        is based on a prior psychiatric diagnosis that is unstable as determined by the subject's
        treating Psychiatrist Dementia as previously diagnosed by a medical practitioner

        â€¢ Safety Laboratory Criteria at the screening visit: Alanine aminotransferase (ALT) &gt;5
        times the upper limit of normal (ULN), OR ALT &gt;3xULN Total bilirubin, lactate,
        triglycerides, amylase, or lipase greater than 2.0 times the upper limit of normal Subject
        has creatinine clearance of &lt;50 mL/min via Cockroft-Gault method Subjects with moderate to
        severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification;
        Absolute neutrophil count of &lt; 1 x 109/L Platelet concentration of &lt; 100 x 109/L
        Haemoglobin &lt; 100g/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Albion Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Macquarie Neurology</name>
      <address>
        <city>North Ryde</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain and Mind Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Health Care Bethlehem</name>
      <address>
        <city>Caulfield South</city>
        <state>Victoria</state>
        <zip>3162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Antiretroviral Therapy, Triumeq</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

